Wockhardt announces Covid-19 vaccine partnership with UK government

0
48

Wockhardt, the global pharmaceutical and biotechnology major has announced that it has entered into an agreement with the UK Government to fill-finish COVID-19 vaccines. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.
As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and licensed by AstraZeneca.
#Wockhardt #Covid19vaccine #UKgovernment
Dr Habil Khorakiwala, Founder Chairman of Wockhardt emphasised, “The pandemic of COVID-19 is a challenge for all and needs a concerted effort to overcome. They are proud to be collaborating with the UK Government to make vaccines available and the arrangement brings in a huge sense of purpose and pride, it upholds their ongoing commitment to fight against such a pandemic of global human importance. As a global organisation, they are focussed and committed to assist in mitigating the worldwide impact of COVID-19.

Speaking about the contract Ravi Limaye, Managing Director Wockhardt UK said, “they are immensely proud to have been selected to partner with the UK Government on this project. In doing so they are taking a lead role in the nation’s fight against pandemic of COVID-19”.
The government has reserved one fill and finish production line for its exclusive use for the next 18 months in order to guarantee the supply of vaccines required to fight COVID-19 in the UK.

Dr Murtaza Khorakiwala, Managing Director and Global CEO of Wockhardt adds, “The arrangement with the UK Government for manufacturing vaccines for COVID-19 showcases the global strength in world class sterile injectable facilities and capacity. With four decades of expertise and experience behind they are able to quickly scale to manufacture and assist in mitigating the worldwide impact of COVID-19.”

Wockhardt is a global pharmaceutical and biotech organisation that brings affordable, high quality medicines to market. In the UK, Wockhardt is one of the largest suppliers into the NHS for over 20 years, has had a presence in Wrexham for over two decades and employs over 400 people at its 612,000 square feet high-tech manufacturing facility.